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Reduced endogenous endothelin-1–mediated vascular tone in
chronic renal failure
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United Kingdom
Reduced endogenous endothelin-1–mediated vascular tone in Endothelin-1 is an endothelium-derived 21-amino acid
chronic renal failure. peptide with sustained vasoconstrictor properties [1]. En-
Background. Endothelin-1 generated by the vascular endo- dothelin-1 is generated from an inactive 38-amino acid
thelium contributes to basal vascular tone and blood pressure precursor, big endothelin-1, through the action of endo-in healthy humans. Plasma concentrations of endothelin-1,
thelin-converting enzyme (ECE), a unique membrane-which are elevated in chronic renal failure (CRF), may contrib-
bound neutral metalloprotease [2]. Endothelin-1 bindsute to increased vascular tone.
Methods. We investigated the contribution of endogenous to at least two receptors [3]: The endothelin A (ETA)
and exogenous endothelin-1 to the maintenance of vascular receptor is present on vascular smooth muscle cells in
tone in patients with CRF (creatinine $ 200 mmol/liter) and which it plays a major role in causing vasoconstriction
in age- and sex-matched healthy subjects. In a series of experi- [4]; the ETB receptor is present on endothelial cells inments, we measured forearm vascular responses to intra-arterial
which it mediates release of endothelium-derived vasodi-norepinephrine (30 to 240 pmol/min), endothelin-1 (5 pmol/min),
lator substances [5], and also on vascular smooth musclethe selective endothelin A (ETA) receptor antagonist BQ-123
cells in which it mediates vasoconstriction [6]. Endoge-(3 mg/hr), the mixed endothelin-converting enzyme and neutral
endopeptidase inhibitor phosphoramidon (30 nmol/min), and nous generation of endothelin-1 has been shown to con-
the selective neutral endopeptidase inhibitor thiorphan (30 tribute to the maintenance of basal vascular tone [4] and
nmol/min). blood pressure [7] in healthy humans.
Results. The maximum reduction in forearm blood flow
Plasma concentrations of immunoreactive big endo-(FBF) to norepinephrine in CRF (33 6 7%) was similar to that
thelin-1 and endothelin-1 are elevated in renal failurein controls (43 6 7%, P 5 0.53). Endothelin-1 also produced
[8, 9]. Because these high plasma endothelin concentra-a similar reduction in FBF in CRF (35 6 6%) and controls
(36 6 5%, P 5 0.81). BQ-123 increased FBF in CRF (11 6 tions may be within a range sufficient to cause vasocon-
4%) but significantly less than in controls (44 6 10%, P 5 striction [10], plasma endothelin-1 may play a role in the
0.02). Phosphoramidon increased FBF in CRF (68 6 20%), development, or maintenance, of hypertension in chronic
again significantly less than in controls (181 6 41%, P 5 0.001). renal failure (CRF). Indeed, plasma endothelin concen-
Thiorphan reduced FBF similarly in CRF (22 6 6%) and con-
trations are positively correlated with blood pressure introls (14 6 6%, P 5 0.39). Responses to phosphoramidon were
hemodialysis patients [11]. This contrasts to findings insubstantially greater than to BQ-123.
patients with mild to moderate essential hypertension inConclusions. These studies show that endogenous genera-
tion of endothelin-1 contributes to the maintenance of resting whom no such relationship was found [12]. However, it is
vascular tone in patients with CRF, as well as in healthy subjects. not known whether endothelin-1 contributes to elevated
Although the contribution of endogenous endothelin-1 to resting basal resistance vessel tone in patients with CRF.
vascular tone appears to be reduced in CRF, ETA receptor Therefore, we have investigated the responses of fore-antagonism, and particularly endothelin-converting enzyme in-
arm resistance vessels to brachial artery infusion of endo-hibition, should be explored as means by which to reduce
thelin-1 and a control constrictor, norepinephrine, in pa-vascular tone and blood pressure in patients with CRF.
tients with stable CRF who were independent of dialysis
and in healthy age- and sex-matched control subjects.
We also examined the contribution of endothelin-1 actingKey words: endothelin receptors, BQ-123, blood pressure, vasocon-
striction, hypertension, renal failure. via the ETA receptor to basal vascular tone by brachial
artery infusion of a maximally effective dose [13, 14] ofReceived for publication January 12, 1998
the specific ETA receptor antagonist, BQ-123 [4, 15]. Weand in revised form September 10, 1998
Accepted for publication September 10, 1998 further examined the contribution of endogenous gener-
ation of endothelin-1 to the maintenance of forearm vas- 1999 by the International Society of Nephrology
613
Hand et al: ET-1–mediated vascular tone in CRF614
cular tone by comparing responses to brachial artery infu- Drugs
sion of the combined ECE and neutral endopeptidase Norepinephrine (30, 60, 120, and 240 pmol/min; Sanofi
(NEP) inhibitor, phosphoramidon [4, 16, 17], with those Winthrop Ltd., Guildford, UK), endothelin-1 (5 pmol/
to the selective NEP inhibitor, thiorphan [4, 17]. min; Clinalfa, Laufelfingen, Switzerland), BQ-123 (3 mg/
hr; American Peptide Company, Sunnyvale, CA, USA),
phosphoramidon (30 nmol/min; Clinalfa), thiorphan (30METHODS
nmol/min; Sigma Chemicals, Poole Dorset, UK), and
Subjects physiologic saline (0.9%; Baxter Healthcare Ltd., Thet-
A total of 11 patients (10 male, 1 female) with estab- ford, UK) were administered at locally but not systemi-
lished chronic renal disease (creatinine $ 200 mmol/liter cally active doses via the brachial artery cannula. These
and stable blood pressure for 6 months or more) caused by doses were based on previous studies [4, 21]. All solu-
IgA nephropathy (N 5 3), obstructive uropathy (N 5 2), tions were made up in physiologic saline. The norepi-
reflux nephropathy (N 5 2), nephrosclerosis (N 5 2), nephrine solutions were made up in physiologic saline
interstitial nephritis (N 5 1), and Alport’s syndrome containing 100 mg/ml ascorbic acid (Evans Medical Ltd.,
(N 5 1) were recruited. All patients were independent Dunstable, UK) to avoid oxidation. The total rate of
of dialysis. Three subjects underwent all of the study intra-arterial infusion was kept constant at 1 ml/min.
protocols. Five subjects underwent the protocols involv-
Designing infusion of norepinephrine, endothelin-1, and BQ-123
only, and three subjects underwent infusion of phos- Studies were performed in a quiet room maintained at
phoramidon and thiorphan only. If patients were taking a constant temperature of between 228C and 258C. After
antihypertensive or other vasoactive medication, this was brachial artery and venous cannulation, saline was infused
withdrawn at least one week before each study. Ten age- via the brachial artery cannula for 30 minutes, and blood
and sex-matched healthy control subjects (nine male, one was withdrawn from the venous cannula to measure
female) who were not taking any vasoactive medication plasma creatinine, endothelin-1, big endothelin-1, and he-
were also recruited, of whom four undertook all the study moglobin. In eight patients with CRF and in eight control
protocols, and four the protocols involving infusion of subjects, norepinephrine was then infused at incremental
norepinephrine, endothelin-1, and BQ-123 only. Two sub- doses (30, 60, 120, and 240 pmol/min, each dose for 6
jects underwent infusion of phosphoramidon and thior- min) via the brachial artery cannula. After infusion of
phan only. All studies were conducted with the approval norepinephrine, saline was infused for 20 minutes to
of the local ethics review committee, and all subjects gave allow for the reversal of vasoconstriction. Endothelin-1
their written informed consent to participate. Subjects was then infused at a single dose of 5 pmol/min for one
avoided nonsteroidal anti-inflammatory drugs for the hour. FBF was recorded at 10-minute intervals during
week before and caffeine-containing drinks or cigarettes infusion of saline and during the last three minutes of
on the day of each study. In addition, subjects fasted for each increment of the norepinephrine infusion and at
at least three hours before each study. 10-minute intervals during the endothelin-1 infusion. On
a separate day, after the 30-minute infusion of saline,
Procedures BQ-123 was infused in these subjects at a single dose of
A 21 SWG cannula was inserted into a vein on the 3 mg/hr for one hour, and FBF was measured at five-
dominant arm under local anesthesia using 1% lidocaine minute intervals. In a further subgroup of three CRF
hydrochloride (Lidocaine; Astra Pharmaceuticals Ltd., patients and seven control subjects, the BQ-123 was in-
Kings Langley, UK) for the purpose of sampling blood. fused at 3 mg/hr and was continued for two hours.
A 27 SWG steel cannula (Cooper’s Needle Works, Bir- In a separate study in six patients with CRF and in
mingham, UK) was inserted into the brachial artery of six control subjects, after a 30-minute infusion of saline,
the nondominant arm, under local anesthesia, for the phosphoramidon or thiorphan was infused, on separate
purpose of intra-arterial infusion of drugs. Forearm blood days, at a single dose of 30 nmol/min for 90 minutes,
flow (FBF) was measured in both arms using venous and FBF was measured at 10-minute intervals.
occlusion plethysmography [18] adapted for use with In all studies, the mean of the final five blood flow
indium-and-gallium-in-silastic strain gauges [4]. Mea- measurements of each recording period was used for
surements were made for 10 seconds in every 15 seconds analysis. Arterial pressure was measured in the nonin-
over a three-minute period. Blood flow to the hands was fused arm immediately after each blood flow recording.
excluded during each three-minute measurement period. In each subject, infusions were on separate days, at least
Arterial pressure was measured using a well-validated one week apart. The order in which the experiments
semiautomated oscillometric method (Takeda UA 751; were undertaken was randomized. However, vasocon-
striction to endothelin-1 is sustained, whereas that toTakeda, Tokyo, Japan) [19, 20].
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norepinephrine is short lasting. Therefore, in the com- and compensates for the continual small adjustments
bined norepinephrine/endothelin-1 study, it was neces- affecting the circulation of both arms that occur even at
sary to give norepinephrine first rather than randomize rest and for other external systemic factors such as the
the order of infusions. level of arousal that may otherwise act as confounding
factors [24].
Analytical All results are expressed as mean 6 sem. Dose–
Venous plasma samples for radioimmunoassay of endo- response relationships were compared using analysis of
thelin-1 and big endothelin-1 were separated within 10 variance. All other parameters were analyzed by Stu-
minutes and were stored at 2808C. Plasma biochemistry dent’s paired or unpaired t-test as appropriate. Statistical
was measured using a Kodak Ectachem System E700 XRC analysis was performed using the STATVIEW 5121e
analyzer (Kodak Diagnostics Ltd., Hemel Hempstead, software (Brain-power Inc., Calabasas, CA, USA) for
Herts., UK) in the Department of Clinical Chemistry, the Apple Macintosh microcomputer. Values of P of less
Western General Hospital (Edinburgh, UK). Hemoglo- than 0.05 were considered statistically significant.
bin was measured in the Department of Hematology,
Western General Hospital, using a Coulter STKS ana-
RESULTSlyzer (Coulter Electronics Ltd., Luton, Beds., UK).
Plasma immunoreactive endothelin-1 and big endothe- There was no significant difference in age, sex, hemo-
lin-1 concentrations were measured using an acetic acid globin, or resting FBF between the patients with CRF
extraction technique [22] and a modified commercial ra- and the healthy control subjects when receiving norepi-
dioimmunoassay using rabbit antihuman endothelin-1 or nephrine, endothelin-1, or BQ-123 (Tables 1 and 2).
big endothelin-1 (Peninsula Laboratories Europe, St. However, resting FBF was higher in patients with CRF
Helens, UK) [23]. Briefly, sample extract was incubated who underwent the phosphoramidon/thiorphan studies
with either endothelin-1 or big endothelin-1 antibody for compared with control subjects (Table 2). FBF in the
24 hours at 48C. Following incubation, 125I-labeled endo- noninfused arm did not change during any infusion pe-
thelin-1 (NEN Life Science Products, Boston, MA, USA) riod apart from when endothelin-1 and thiorphan was
or big endothelin-1 (Peninsula Laboratories Europe) was infused in control subjects (Table 2) when the FBF in
added, and incubation was continued for an additional the control arm increased, whereas the blood flow in the
20 hours at 48C. Complexes were precipitated with Amer- infused forearm decreased. Plasma creatinine and mean
lexe donkey antirabbit antibody (Amersham Life Sci- arterial pressure were elevated in the CRF groups when
ences Ltd., Little Chalfont, Bucks., UK) and were counted compared with control subjects (Table 1). The plasma
for radioactivity. All endothelin values were expressed immunoreactive endothelin-1 concentration was higher
as picograms per milliliter. Recovery of endothelin-1 and in CRF patients (3.9 6 0.2 pg/ml, N 5 9) than in control
big endothelin-1 was 89% and 91%, respectively. Intra- subjects (2.9 6 0.2 pg/ml, N 5 10, P 5 0.0001). Similarly,
assay and interassay coefficients of variations in our labo- the plasma immunoreactive big endothelin-1 concentra-
ratory are 6.3% and 7.2%, respectively; the sensitivity
tion was higher in the CRF patients (43.5 6 4.0 pg/ml,
of the assay for endothelin-1 was 0.25 pg/ml, and for big
N 5 9) than in control subjects (31.4 6 3.5 pg/ml, N 5endothelin-1, sensitivity was 1 pg/ml.
10, P 5 0.03).Cross-reactivities of the endothelin-1 assay were endo-
thelin-1 (100%), endothelin-2 (0%), endothelin-3 (0%), Infusion of norepinephrine and endothelin-1
and big endothelin-1 (10%). The cross-reactivities of the
Norepinephrine caused a dose-dependent reductionbig endothelin-1 assay were endothelin-1 (0%), endo-
in FBF (Fig. 1 and Table 2) with a change in blood flowthelin-2 (0%), endothelin-3 (0%), and big endothelin-1
at the highest dose of 233 6 7% in patients with CRF(100%).
and 243 6 7% in control subjects, which was similar
between the two groups (P 5 0.53). Saline infusion fol-Data presentation and statistics
lowing the norepinephrine infusion allowed FBFs to re-Mean arterial pressure was calculated as diastolic arte-
turn to baseline flows of 2.8 6 0.3 ml/100 ml/min beforerial pressure plus one-third pulse pressure. FBF was cal-
endothelin-1 and 3.1 6 0.6 ml/100 ml/min before norepi-culated in milliliters per 100 ml of forearm tissue per
nephrine (P 5 0.40) for patients and, similarly, 2.9 6 0.2minute. The ratio of FBF in the infused arm compared
ml/100 ml/min before endothelin-1 and 3.4 6 0.4 ml/100with that in the control arm was calculated for each
ml/min before norepinephrine (P 5 0.24) for controlmeasurement period. The ratio of FBF (infused:control
subjects. Endothelin-1 caused a progressive reduction inarm) was measured in response to drugs and was ex-
FBF (Fig. 2 and Table 2) with a change in blood flowpressed as a percentage of the ratio (infused:control arm)
after 60 minutes of infusion of 235 6 6% in patientsmeasured during the control period [24]. This method
uses the noninfused arm as a contemporaneous control with CRF and 236 6 5% in control subjects (P 5 0.81).
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Table 1. Subject characteristics
Norepinephrine/
endothelin-1 BQ-123 Phosphoramidon Thiorphan
Control CRF Control CRF Control CRF Control CRF
Number 8 8 8 8 6 6 6 6
Age years 46 6 5 47 6 6 46 6 5 47 6 6 40 6 8 41 6 8 40 6 8 41 6 8
Sex M/F 7/1 7/1 7/1 7/1 6/0 6/0 6/0 6/0
Hemoglobin g/dl 12.7 6 0.5 11.1 6 0.8 12.7 6 0.5 11.1 6 0.8 13.0 6 0.6 11.6 6 0.7 13.0 6 0.6 11.6 6 0.7
Creatinine lmol/liter 87 6 5 391 6 54a 87 6 5 391 6 54a 84 6 7 449 6 66a 84 6 7 449 6 66a
Mean arterial pressure mm Hg 88 6 3 104 6 2a 85 6 3 100 6 4a 86 6 4 110 6 6a 87 6 6 108 6 4b
Results are expressed as mean 6 sem.
a P , 0.002, b P # 0.05 when compared to control subjects
Table 2. Forearm blood flows (FBF) before and during infusions
Norepinephrine Endothelin-1 BQ-123 Phosphoramidon Thiorphan
Control CRF Control CRF Control CRF Control CRF Control CRF
Control arm FBF
ml/100 ml/min
Basal 2.460.2 3.060.6 2.760.3 2.860.5 2.460.3 3.260.4 2.9 60.4 3.4 60.4 1.760.2 3.960.7a
End of infusion 2.9 60.3 2.860.6 3.260.4b 3.060.7 2.160.3 3.5 60.6a 3.660.7 3.560.4 2.56 0.3b 2.86 0.7c
Infused arm FBF
ml/100 ml/min
Basal 3.060.3 3.160.6 2.960.2 2.860.3 2.660.3 3.760.5 2.560.4 4.6 60.8a 1.960.2 5.461.3a
End of infusion 2.0 60.2b 1.860.2b 2.460.3b 1.860.3b 3.260.4b 4.560.7b 7.460.8b 6.960.7b 2.460.3b 3.960.7b,c
a P , 0.05 for resting blood flow when compared to control subjects (t-test)
b P , 0.05, compared to basal value (paired t-test)
c P , 0.05, compared to control response to infusion (ANOVA)
Infusion of BQ-123 DISCUSSION
We have shown, using the ECE inhibitor, phosphora-Infusion of BQ-123 caused a progressive increase in
midon, and the ETA antagonist, BQ-123, that endoge-FBF (Fig. 3 and Table 2), maximal at 60 minutes, of
nous endothelin-1 contributes to the maintenance of rest-11 6 4% in patients with CRF and 44 6 10% in control
ing forearm vascular tone in patients with CRF. We havesubjects; the response in patients with CRF was signifi-
also demonstrated, using BQ-123, that the contributioncantly reduced (Fig. 3) when compared with that of the
of endothelin-1 to resting vascular tone mediated throughcontrol subjects (P 5 0.02). In those subjects undergoing
the ETA receptor is decreased in patients with CRF com-the two-hour infusion, there was no further vasodilation
pared with healthy controls. In addition, using phos-after 60 minutes of BQ-123 in either patients (13 6 11%
phoramidon, the reduced contribution of endothelin-1at 60 min, 23 6 3% at 120 min, P 5 0.35) or control
to the maintenance of vascular tone in patients with CRFsubjects (46 6 11% at 60 min, 48 6 9% at 120 min, P 5
appears to be due at least in part to reduced generation0.76), respectively.
of endothelin-1. These functional responses are in con-
trast to the observed elevated concentrations of endo-Infusion of phosphoramidon and thiorphan
thelin-1 and big endothelin-1 in CRF.
Infusion of phosphoramidon caused a progressive in- These studies involved infusion of locally but not sys-
crease in FBF (Fig. 4 and Table 2), maximal at 90 min- temically active doses of vasoactive agents into the fore-
utes, of 68 6 20% in patients with CRF and 181 6 41% arm vascular bed. Indeed, FBF in the noninfused arm
in control subjects. The response of the patients with did not change during any infusion period apart from
CRF to phosphoramidon was reduced (Fig. 4) when com- when endothelin-1 and thiorphan were infused in control
pared with that of the control subjects (P 5 0.001). Infu- subjects (Table 2), when the FBF in the control arm
sion of thiorphan caused a progressive reduction in FBF increased and the blood flow in the infused forearm
(Table 2), maximal at 90 minutes, of 222 6 6% in pa- decreased. The use of locally active doses of vasoactive
tients with CRF and 214 6 6% in control subjects and agents is important in these studies, as systemic doses
was similar when comparing the two groups (P 5 0.39; may obscure any direct vascular action through effects
on other organs, such as the heart and kidney, or throughFig. 4).
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Fig. 3. Effect of BQ-123 infusion on FBF. Symbols are: (d) patients
with CRF and (s) healthy control subjects (P 5 0.02 by ANOVA).
activation of reflex mechanisms caused by changes in
blood pressure [25]. The forearm vascular bed was cho-
Fig. 1. Effect of norepinephrine infusion on forearm blood flow (FBF). sen because the responses to vasoactive agents within
Symbols are: (d) patients with CRF and (s) healthy control subjects
this vascular bed are thought to be broadly representa-(P 5 0.53 by ANOVA).
tive of responses in other functionally important resis-
tance beds [25, 26].
In contrast to the impaired responsiveness of the fore-
arm resistance vessels to norepinephrine in patients with
CRF who are dialysis dependent and anemic [21], there
was no difference in the responsiveness to norepineph-
rine of the forearm resistance vessels between the dial-
ysis-independent CRF patients and control subjects in
this study. Also, in response to infusion of endothelin-1,
there was a progressive vasoconstriction that was of a
similar magnitude in the patients and control subjects,
suggesting that responsiveness to endothelin-1 is not re-
duced in CRF in the way it is in chronic heart failure [27].
In addition, similar vascular responsiveness to infusion of
norepinephrine and endothelin-1 in CRF patients and
control subjects implies vascular functional integrity with
respect to these two endogenous vasoactive mediators.
The specific ETA receptor antagonist BQ-123 produced
a progressive vasodilation in both patients with CRF and
the control subjects, implying that endothelin-1, acting
through the ETA receptor, has a role in the maintenance
of resting vascular tone. Furthermore, we have demon-
strated, in both patients and controls, that the response
to BQ-123 was maximal at 60 minutes. However, the
response to BQ-123 in the patient group was significantlyFig. 2. Effect of endothelin-1 infusion on FBF. Symbols are: (d) pa-
tients with CRF and (s) healthy control subjects (P 5 0.81 by ANOVA). impaired when compared with control subjects. This im-
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investigate potential changes in ETB receptor function
in CRF.
Third, the altered response to infused BQ-123 in CRF
may occur as a consequence of diminished responsiveness
of the vascular smooth muscle cell in CRF. However,
our findings of similar responsiveness to exogenous en-
dothelin-1 between patients with CRF and control sub-
jects are against this hypothesis.
Fourth, despite the increased concentrations of immu-
noreactive endothelin-1 and big endothelin-1 observed by
our experiments and others [9], concentrations of biologi-
cally active endothelin-1 may be decreased in patients with
CRF as a consequence of impaired generation of endo-
thelin-1. Fractionation of plasma samples reveals that
the elevation in immunoreactive endothelin-1 in CRF may
be due to marked increases in immunoreactive big endo-
thelin-1 degradation products [29] rather than biologi-
cally active endothelin-1. Furthermore, Shichiri reported
similar concentrations of immunoreactive endothelin-1
in patients with renal failure and healthy control subjects
when using an assay that does not cross-react with either
big endothelin-1 or the C-terminal fragment [30].
Fifth, the increased blood pressure observed in the
patients with CRF may contribute to the different re-
sponses between the CRF group and the control subjects
rather than the altered renal function. However, this is
unlikely because a study similar to ours found no differ-
ence in response to BQ-123 when comparing hyperten-
sive subjects with normal renal function and control sub-
Fig. 4. Effect of phosphoramidon and thiorphan infusion on FBF. Sym-
jects [13]. Also against this is the inverse relationshipbols are: patients with CRF receiving phosphoramidon (d) and thior-
phan (j) and healthy control subjects receiving phosphoramidon (s, between blood pressure and forearm vascular respon-
P 5 0.001 by ANOVA) and thiorphan (h, P 5 0.39 by ANOVA). siveness to endothelin-1 in patients with dialysis-depen-
dent renal failure using human recombinant erythropoie-
tin [21].
Sixth, BQ-123–induced vasodilation may not only oc-paired response may have occurred for several reasons.
cur as a consequence of abolition of a constrictor stimu-First, elevated circulating concentrations of biologically
lus but may, in part, be mediated by nitric oxide–active endothelin-1, either as a result of increased gener-
dependent vasodilator tone [31]. The reduced responseation or decreased clearance, may have been sufficiently
to BQ-123 observed in the CRF subjects may reflect anhigh that the dose of BQ-123 used was not sufficient to
abnormality in nitric oxide-mediated vascular tone, possi-block the ETA receptor. However, because the dose of
bly as a consequence of impaired endothelial function asBQ-123 infused was at least 10-fold higher than that
described in patients with end-stage renal failure [32].previously shown to cause a maximal effect in the fore-
Infusion of the NEP and ECE inhibitor, phosphorami-arm in healthy subjects [13, 14], this is unlikely to be the
don, caused forearm vasodilation. In contrast, infusionexplanation.
of the selective NEP inhibitor thiorphan caused a slow-Second, in renal failure, endothelin-1 may cause vaso-
onset vasoconstriction that was similar between the pa-constriction by acting on the ETB receptor. ETB agonists
tients with CRF and control subjects. The vasodilatorcan cause vasoconstriction [6]. Our observations in renal
effect of the infused phosphoramidon was thereforefailure may be consistent with those in chronic heart
likely to be an action of inhibiting ECE rather than NEPfailure where there appears to be a relative up-regulation
[4]. Vasodilation of the forearm vasculature in responseof the constrictor ETB receptor [27, 28]. ETB-mediated
to phosphoramidon suggests that endothelin-1 genera-vasoconstriction in CRF may be of greater importance
tion by the vascular endothelium is important in thethan in heart failure because ETB-mediated vasodilation
maintenance of resting vascular tone in healthy subjectsmay be reduced, perhaps as a result of endothelial dys-
and shows that this is also the case in patients with CRF,function, in CRF patients as compared with healthy sub-
jects. However, our studies were not designed to fully although to a lesser extent. Given that constriction to
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